RCAT vs. KROS

Last updated Apr 1, 2026

Compare and contrast key facts about Red Cat Holdings, Inc. (RCAT) and Keros Therapeutics, Inc. (KROS).

Performance

RCAT vs. KROS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Red Cat Holdings, Inc. (RCAT) and Keros Therapeutics, Inc. (KROS). The values are adjusted to include any dividend payments, if applicable.

RCAT vs. KROS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
RCAT Red Cat Holdings, Inc.	65.07%	-38.29%	1,360.23%	-6.38%	-54.81%	-30.67%	300.00%
KROS Keros Therapeutics, Inc.	-45.78%	28.62%	-60.19%	-17.20%	-17.93%	-17.05%	251.29%

Fundamentals

Market Cap RCAT : $1.56B KROS : $417.96M
EPS RCAT : -$0.71 KROS : $2.19
PS Ratio RCAT : 32.62 KROS : 1.80
PB Ratio RCAT : 6.36 KROS : 1.38
Total Revenue (TTM) RCAT : $40.73M KROS : $244.06M
Gross Profit (TTM) RCAT : $1.28M KROS : $242.91M
EBITDA (TTM) RCAT : -$60.91M KROS : $82.26M

Returns By Period

In the year-to-date period, RCAT achieves a 65.07% return, which is significantly higher than KROS's -45.78% return.

RCAT

• 1D: 12.94%
• 1M: 12.36%
• YTD: 65.07%
• 6M: 26.47%
• 1Y: 122.62%
• 3Y*: 132.61%
• 5Y*: 25.14%
• 10Y*: —

KROS

• 1D: 3.37%
• 1M: -22.20%
• YTD: -45.78%
• 6M: -30.21%
• 1Y: 8.34%
• 3Y*: -36.29%
• 5Y*: -28.42%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RCAT vs. KROS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RCAT

RCAT Risk / Return Rank: 77
RCAT Sharpe Ratio Rank: 76
RCAT Sortino Ratio Rank: 80
RCAT Omega Ratio Rank: 74
RCAT Calmar Ratio Rank: 78
RCAT Martin Ratio Rank: 75

KROS

KROS Risk / Return Rank: 44
KROS Sharpe Ratio Rank: 47
KROS Sortino Ratio Rank: 45
KROS Omega Ratio Rank: 45
KROS Calmar Ratio Rank: 42
KROS Martin Ratio Rank: 43

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RCAT vs. KROS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Red Cat Holdings, Inc. (RCAT) and Keros Therapeutics, Inc. (KROS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RCAT	KROS	Difference
Sharpe ratio Return per unit of total volatility	1.03	0.17	+0.85
Sortino ratio Return per unit of downside risk	2.03	0.62	+1.41
Omega ratio Gain probability vs. loss probability	1.23	1.08	+0.16
Calmar ratio Return relative to maximum drawdown	2.03	0.05	+1.99
Martin ratio Return relative to average drawdown	4.43	0.14	+4.29
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RCAT vs. KROS - Sharpe Ratio Comparison

The current RCAT Sharpe Ratio is 1.03, which is higher than the KROS Sharpe Ratio of 0.17. The chart below compares the historical Sharpe Ratios of RCAT and KROS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RCAT	KROS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.03	0.17	+0.85
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.22	-0.42	+0.64
Sharpe Ratio (All Time) Calculated using the full available price history	-0.06	-0.14	+0.08

Correlation

The correlation between RCAT and KROS is 0.08, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RCAT vs. KROS - Dividend Comparison

Neither RCAT nor KROS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RCAT vs. KROS - Drawdown Comparison

The maximum RCAT drawdown since its inception was -99.76%, which is greater than KROS's maximum drawdown of -88.46%. Use the drawdown chart below to compare losses from any high point for RCAT and KROS.

Drawdown Indicators

	RCAT	KROS	Difference
Max Drawdown Largest peak-to-trough decline	-99.76%	-88.46%	-11.30%
Max Drawdown (1Y) Largest decline over 1 year	-60.08%	-51.42%	-8.66%
Max Drawdown (5Y) Largest decline over 5 years	-92.25%	-86.45%	-5.80%
Current Drawdown Current decline from peak	-92.15%	-86.66%	-5.49%
Average Drawdown Average peak-to-trough decline	-95.58%	-47.26%	-48.32%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.61%	16.76%	+10.85%

Volatility

RCAT vs. KROS - Volatility Comparison

Red Cat Holdings, Inc. (RCAT) has a higher volatility of 37.54% compared to Keros Therapeutics, Inc. (KROS) at 19.72%. This indicates that RCAT's price experiences larger fluctuations and is considered to be riskier than KROS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RCAT	KROS	Difference
Volatility (1M) Calculated over the trailing 1-month period	37.54%	19.72%	+17.82%
Volatility (6M) Calculated over the trailing 6-month period	84.17%	36.41%	+47.76%
Volatility (1Y) Calculated over the trailing 1-year period	120.21%	48.82%	+71.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	114.24%	68.56%	+45.68%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	251.41%	70.16%	+181.25%

Financials